Antimalarial therapy for granuloma annulare: Results of a retrospective analysis
To the Editor: Granuloma annulare (GA) is a relatively common granulomatous skin disease that most often presents as erythematous annular plaques with central clearing. Lesions may be localized (''localized GA''), widespread (''generalized GA''), or present as subcutaneous nodules (''subcutaneous GA'').
GA is benign and largely asymptomatic. However, its epidemiology, comorbidities, and treatment protocols are poorly defined. 1 Published work often lacks comprehensive evaluation of GA cohorts, histologic confirmation, 1,2 or combines GA variants. Whereas antimalarials have been proposed in the treatment of GA, reports of their use are scarce, with the largest studies conducted decades ago. 1 To address these limitations, we retrospectively reviewed charts of all GA patients seen within the granulomatous skin disease clinic at the University of Pennsylvania (Penn) from 2009 to 2016 (by M.R.). Initial search criteria within PennSeek, a tool allowing querying of Penn's electronic medical records, required that patients either 1) received an International Classification of Diseases code for GA or 2) had ''GA'' or ''granuloma annulare'' written in their chart. This yielded 63 patients. A manual chart review identified 35 patients who were ultimately diagnosed with GA. All cases were histologically confirmed.
For each patient, the following information was retrieved (Table I) : demographics, GA clinical variant, antimalarial response, and the presence of comorbidities previously reported in association with GA. Treatment response was determined from clinical notes. Table I describes the characteristics of our GA cohort. Eighty percent were female; the mean age at diagnosis was 54 years (range, 28-79 years). More than three-quarters (77.1%) of patients had generalized GA (n ¼ 27), 17.1% had localized GA (n ¼ 6), and 5.7% had subcutaneous GA (n ¼ 2). Five patients had features of annular elastolytic giant cell granuloma.
The prevalence of diabetes, dyslipidemia, and hypothyroidism is the United States is estimated at 17.5% ( for patients 45-64 years of age), 3 29.4% ( for patients 55-64 years of age without cardiovascular disease), 4 and 6.1% ( for patients 50-59 years of age), 5 respectively. In contrast, our GA cohort was of a similar age group, yet had a higher prevalence of these comorbidities. More than half (63.2%) had some form of glucose intolerance; 31.6% were diabetic. Eighty percent had dyslipidemia and 37% had thyroid disease. Ten of 18 patients (55.6%) improved on hydroxychloroquine (Fig 1) . Nearly all patients prescribed hydroxychloroquine had previously failed or experienced inadequate response from alternative GA treatments, the most common of which were topical steroids (n ¼ 12), intralesional triamcinolone acetonide (n ¼ 10), topical tacrolimus (n ¼ 5), and minocycline (n ¼ 5). All 6 patients prescribed chloroquine improved (100%), 5 of whom had earlier failed treatment with hydroxychloroquine. The average treatment duration with hydroxychloroquine and chloroquine before noting improvement was 3.6 and 3 months, respectively. Our study is limited by its small size, the lack of standardized tools available to assess GA severity and treatment efficacy, and its retrospective cross-sectional nature. To our knowledge, this is the largest cohort of GA patients treated with hydroxychloroquine, and further emphasizes the potential association of GA with thyroid disease. 1 Notably, our tertiary referral cohort included predominantly patients with generalized GA, while 70% of GA cases are localized in general practice. y Four hundred mg daily (maximum 6.5 mg/kg ideal body weight); some patients were treated with 200-300 mg/daily. Of the 18 patients prescribed hydroxychloroquine, 11 received 400 mg/daily, 3 received 300 mg/daily, and 4 received 200 mg/daily. Three of the 18 patients prescribed hydroxychloroquine chose to discontinue because of diarrhea (n ¼ 2) and hair loss (n ¼ 1). A fourth patient reported mild gastrointestinal symptoms that eventually self-resolved. z Two hundred fifty mg/day either 5 days a week (n ¼ 5) or 3 days a week (n ¼ 1). Of the 6 patients prescribed chloroquine, 1 discontinued because of development of bronchiolitis.
x n reflects the denominator for each calculation. In order to be included in prevalence calculations for comorbidities, a given patient with GA must have either (1) received a diagnostic code for the particular comorbidity OR (2) been screened at least once for the relevant comorbid condition. k Of 20 patients with dyslipidemia, the number of patients with pure hypercholesterolemia, pure hypertriglyceridemia, and mixed dyslipidemia were 16, 2, and 2, respectively. Sixteen of the patients with dyslipidemia were also assessed for glucose intolerance. Of these 16 patients, 5 had diabetes, 6 were prediabetic, and 5 had isolated dyslipidemia. { All 10 patients with thyroid disease were hypothyroid. Three were hypothyroid as a result of thyroidectomies performed for various indications ( follicular adenoma, benign thyroid cyst, and papillary thyroid cancer). Of the remaining 7 cases, the etiology was only noted for 1 patient, who had Hashimoto disease. # Two of the 6 patients with localized GA (33%) had features of annular elastolytic giant cell granuloma. **Three of the 27 patients with generalized GA (11.1%) had features of annular elastolytic giant cell granuloma. Well-controlled population-based cohort studies are needed to investigate potential associations between GA and comorbidities, particularly thyroid disease. Dermatologists should consider antimalarials as first-line treatment for generalized GA.
